ENDRA Life Sciences Inc. (NDRA) News
Filter NDRA News Items
NDRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NDRA News Highlights
- For NDRA, its 30 day story count is now at 2.
- Over the past 8 days, the trend for NDRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NDRA are DE and DRUG.
Latest NDRA News From Around the Web
Below are the latest news stories about ENDRA LIFE SCIENCES INC that investors may wish to consider to help them evaluate NDRA as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayWe're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! |
Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023ANN ARBOR, Mich., September 07, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled "Thermoacoustic assessment of fatty liver disease - a clinical feasibility study" for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia. |
ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDAANN ARBOR, Mich., August 30, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company's De Novo request for the TAEUS liver system has advanced to substantive review with the U.S. Food and Drug Administration (FDA). The TAEUS system is ENDRA’s proprietary device that is intended to offer clinicians a tool for the non-invasive assessment of fatty liver tissue, as an aid in the management of patien |
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European PatentsANN ARBOR, Mich., August 23, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe. ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS® system with its novel hybrid ultrasound and thermoacoustic imaging technology. |
ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2023 Earnings Call TranscriptENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2023 Earnings Call Transcript August 14, 2023 Operator: Good day, and welcome to the ENDRA Life Sciences Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this […] |
Q2 2023 ENDRA Life Sciences Inc Earnings CallQ2 2023 ENDRA Life Sciences Inc Earnings Call |
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business UpdateANN ARBOR, Mich., August 14, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and recent weeks include: |
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDAANN ARBOR, Mich., August 14, 2023--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the submission of a De Novo request to the U.S. Food and Drug Administration (FDA) for the TAEUS system. The TAEUS system is ENDRA’s proprietary device that is intended to offer clinicians a tool for the non-invasive assessment of fatty liver tissue, as an aid in the management of patients with Non-Alcoholic Fatty Liver Disease |
ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023ANN ARBOR, Mich., August 01, 2023--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three and six months ended June 30, 2023 on Monday, August 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate development |
Domino's Pizza teams up with Uber for food delivery partnershipDomino's Pizza customers may soon be able to order dinner on the Uber Eats app. Domino's stock jumped on the news that, for the first time, its teaming up with an outside delivery partner. Yahoo Finance Live discusses what this partnership means for the company. |